Drug Delivery. Reimagined
Next-generation lipid-based therapies for hard-to-treat diseases
Drug Delivery.
Reimagined
Next-generation lipid-based therapies
for hard-to-treat diseases
ReviumRx is a preclinical biotechnology company developing next-generation, lipid-based therapies to address some of the most pressing challenges in medicine.
ReviumRx (NASDAQ OTC: RVRC)
Expanding Therapeutic Horizons of Hard-to-Treat Diseases
We are dedicated to tackling unmet medical needs in antimicrobial resistance and oncology by developing lipid-based therapeutics.
Addressing some of the
most pressing challenges in medicine.
Antimicrobial resistance (AMR) is considered a silent pandemic and one of the top global health threats.
1.45 M
deaths
worldwide
40 M
deaths
by 2050
Unleashing the Potential of Targeted Therapeutics
Our approach combines established pharmacology with advanced lipid delivery systems to enhance drug efficacy, optimize safety, and enable targeted treatments when existing therapies fall short.
Our Pipeline
Treatment Indications
We are committed to bringing solutions to unmet medical needs in resistant microbial infections, cancer, and immunization through innovative lipid-based technologies and proven therapeutics.
Immunization
Revium’s lipid-based Protein-Loaded Technology (LPLT) offers a novel and adaptable platform designed to adress unmet needs in immunization.
Solid tumors
Revium Rx is developing nanoparticle-encapsulated candesartan as a tumor-targeted and safe adjuvant to ICIs and other leading chemotherapy-based treatments.
Anti-Microbial
Resistance (AMR)
Revium Rx’s nano-mupirocin is a liposomal formulation of the approved, highly effective antibacterial drug mupirocin, which is currently limited to topical use.
Our Technology:
A Smarter Way to Deliver Powerful Medicines
Revium Rx is building on proven science to tackle some of the toughest challenges in medicine.
Our approach is inspired by the success of a well-known cancer drug called doxorubicin, which was the first FDA-approved treatment to use nanotechnology for drug delivery. Our work is guided by Professor Chezy Barenholz, a world leader in this field and one of the original innovators behind liposomal drug delivery. His decades of research have shaped some of today’s most important cancer treatments.
How it works:
Harnessing the power of liposomal drug delivery
Smart carriers
We use tiny, specially designed fat-based particles called liposomes to carry powerful medicines directly to where they’re needed in the body.
Sustained delivery
The carriers keep drugs circulating longer in the bloodstream and deliver them directly to their target.
Controlled targeted release
Using the EPR effect, the treatment concentrates in diseased tissues like tumors and infected areas, while avoiding healthy cells.
Therapeutic Advantages
Liposomal drug delivery is one of the most advanced ways to deliver medicine
Targeted delivery
allows medicines to reach their target
more precisely
Controlled release
concentrates the treatments in diseased tissues, while avoiding healthy cells.
Extended circulation time
allows the drugs to stay in the
bloodstream longer
Greater efficacy,
fewer side effects
treatments that are more effective and
have a reduced risk of side effects
Backed by scientific research
The efficacy of liposomal drug delivery was highlighted in multiple publications.
-
![Book cover titled 'De G' by De Gruyter, featuring a minimalistic design with abstract pink bubbles on a light background.]()
Nano-mupirocin: enabling the parenteral activity of mupirocin. Mupirocin is an antibiotic having a unique mode of action...
-
![Front cover of a book published by Elsevier featuring a classic black and white illustration of a man and a tree with a Latin phrase banner, "NON SOLUS." The background is light blue with subtle patterning.]()
Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections...
-
![A book cover with a light blue and white background featuring molecular structures, with a dark green pharmacy symbol and the word 'pharmaceutics' in teal handwriting style.]()
Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria...
-
![Book cover with illustration of a tree and a person, and the word "ELSEVIER" in orange.]()
New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage..
-
![Cover of a journal titled 'Journal of Pharmaceutical Sciences' with a blurred background of berries and a white cover.]()
Effect of Solubilizing Agents on Mupirocin Loading into and Release from PEGylated Nanoliposomes...
-
![Cover of a publication by the American Society for Microbiology with a red and white logo and background image of microscopic organisms.]()
In Vitro Susceptibility of Neisseria gonorrhoeae Strains to Mupirocin, an Antibiotic Reformulated for Parenteral ...
Experienced Leadership Team
-
![Portrait of a man with short dark hair, wearing a light blue button-up shirt, against a plain white background.]()
Dr. Erez Koren | CTO
Erez joined Revium in 2023, bringing over 15 years of experience in pharma and biotech R&D.
He previously served as Head of Early-Stage CMC at Clexio Biosciences, where he was responsible for formulation development and phase 1-2 regulatory submissions. Prior to that, Erez led the Innovative R&D Pharma Lab at Teva Pharmaceuticals. He also led CMC activities at Lipocure Ltd. and contributed to the FDA submission and approval of a liposomal drug product (ANDA). Erez holds a Ph.D. in pharmaceutical sciences and completed postdoctoral training at Northeastern University (Boston, MA). Erez has authored over 40 peer-reviewed papers and contributed to five patent applications.
-
![Close-up portrait of a woman with wavy brunette hair, wearing makeup, earrings, and a black top, against a plain background.]()
Inna Martin | Director and COO
Inna brings over 20 years of experience in venture financing, portfolio management and M&As.
Prior to joining Revium, Inna co-founded SPAS™, an innovative cardiovascular solution which is now being adopted by several leading clinics in the US. Inna served as a managing partner at a $760 million sovereign fund focused on healthcare innovation where she managed a portfolio of medical devices and pharmaceutical companies with a combined exit value of over $1.5 billion. Inna has served on the boards of multiple US and Israeli startup companies.
-
![A professional headshot of a man with short dark hair, wearing a dark suit, white shirt, and patterned tie, against a white background.]()
Amir Avraham | Interim CEO
Amir Avraham is a senior finance executive with over 20 years of leadership experience across high-tech and biotech sectors, specializing in financial strategy, M&A, and international operations.
As CFO and General Manager of OCON Therapeutics,, he led strategic planning and capital raises totaling over $15 million while managing legal, financial, and global activities. Previously, he was CFO at Secure Islands Technologies, a cybersecurity firm acquired by Microsoft. There, he led financial operations across the US, UK, and Switzerland, managed investor relations, and was instrumental in both a $20 million fundraising round and the Microsoft acquisition process. Earlier in his career, he held leadership roles at Van Leer Ventures and Deloitte. Mr. Avraham is a licensed CPA and holds an MBA in Finance from the Hebrew University of Jerusalem.
-
![A portrait of a man with short dark hair, wearing a white shirt, against a plain white background.]()
Arie Gordashnikov | CFO
Arie brings to Revium 14 years of experience in accounting, audit and financial management of hi-tech and biotechnology companies.
Since 2018, he serves as Head of IPO & M&A Department at a one of the leading accounting firms of Israel. Prior to that, Mr. Gordashnikov served as an Audit Manager at Ernst & Young Israel. Mr. Arie is licensed CPA since 2012 and has extensive experience in RCC and PCAOB reporting.
-
![Portrait of a middle-aged man with short gray hair, wearing a blue collared shirt, looking at the camera with a neutral expression.]()
Ohad Rosenzweig | VP R&D
Ohad is a seasoned pharmaceutical executive with over two decades of experience in drug development, CMC, and regulatory affairs.
He has led formulation and regulatory strategy efforts across a range of therapeutic areas and development stages. Prior to joining ReviumRx, Ohad held senior leadership roles at Insightec (TASE: EMTC), Rafa Laboratories, Tiltan Pharma, and BioLineRx (Nasdaq: BLRX), where he led the development of both innovative and generic drug products, including sterile injectables, semi-solids, and oral formulations.
Ohad holds a Ph.D. in Pharmaceutics, an MBA, and a B.Pharm from the Hebrew University of Jerusalem.
-
![A man with glasses, a shaved head, and a goatee, wearing a dark suit, light blue shirt, and tie, smiling at the camera]()
Yoram Druker | VP Business Development
Yoram Drucker is a serial entrepreneur with over 25 years of experience in business development, fundraising, and executive roles in the biotechnology sector.
He co-founded and contributed to the development of three publicly-traded biotech companies, including Brainstorm (NASDAQ:BCLI), where he served as COO and CEO, and Pluri Biotech (NASDAQ: PLUR; TLV:PLUR).
